» Articles » PMID: 27129212

Central Mechanisms Mediating Thrombospondin-4-induced Pain States

Abstract

Peripheral nerve injury induces increased expression of thrombospondin-4 (TSP4) in spinal cord and dorsal root ganglia that contributes to neuropathic pain states through unknown mechanisms. Here, we test the hypothesis that TSP4 activates its receptor, the voltage-gated calcium channel Cavα2δ1 subunit (Cavα2δ1), on sensory afferent terminals in dorsal spinal cord to promote excitatory synaptogenesis and central sensitization that contribute to neuropathic pain states. We show that there is a direct molecular interaction between TSP4 and Cavα2δ1 in the spinal cord in vivo and that TSP4/Cavα2δ1-dependent processes lead to increased behavioral sensitivities to stimuli. In dorsal spinal cord, TSP4/Cavα2δ1-dependent processes lead to increased frequency of miniature and amplitude of evoked excitatory post-synaptic currents in second-order neurons as well as increased VGlut2- and PSD95-positive puncta, indicative of increased excitatory synapses. Blockade of TSP4/Cavα2δ1-dependent processes with Cavα2δ1 ligand gabapentin or genetic Cavα2δ1 knockdown blocks TSP4 induced nociception and its pathological correlates. Conversely, TSP4 antibodies or genetic ablation blocks nociception and changes in synaptic transmission in mice overexpressing Cavα2δ1 Importantly, TSP4/Cavα2δ1-dependent processes also lead to similar behavioral and pathological changes in a neuropathic pain model of peripheral nerve injury. Thus, a TSP4/Cavα2δ1-dependent pathway activated by TSP4 or peripheral nerve injury promotes exaggerated presynaptic excitatory input and evoked sensory neuron hyperexcitability and excitatory synaptogenesis, which together lead to central sensitization and pain state development.

Citing Articles

The VGCC auxiliary subunit α2δ1 is an extracellular GluA1 interactor and regulates LTP, spatial memory, and seizure susceptibility.

Leana-Sandoval G, Kolli A, Sandoval M, Saavedra E, Li K, Chen L bioRxiv. 2024; .

PMID: 39677598 PMC: 11642997. DOI: 10.1101/2024.12.02.626379.


The Voltage-Gated Calcium Channel α2δ Subunit in Neuropathic Pain.

Guo S, Shi Y, Zheng Y, Liu H, Zheng Y Mol Neurobiol. 2024; 62(2):2561-2572.

PMID: 39136907 DOI: 10.1007/s12035-024-04424-w.


FTY720/Fingolimod mitigates paclitaxel-induced Sparcl1-driven neuropathic pain and breast cancer progression.

Singh S, Weigel C, Brown R, Green C, Tuck C, Salvemini D FASEB J. 2024; 38(15):e23872.

PMID: 39126272 PMC: 11607628. DOI: 10.1096/fj.202401277R.


Conditional Knockout of Neurexins Alters the Contribution of Calcium Channel Subtypes to Presynaptic Ca Influx.

Brockhaus J, Kahl I, Ahmad M, Repetto D, Reissner C, Missler M Cells. 2024; 13(11.

PMID: 38891114 PMC: 11171642. DOI: 10.3390/cells13110981.


The role of voltage-gated calcium channel α2δ-1 in the occurrence and development in myofascial orofacial pain.

Lu Y, Wang J, Li L, Zhang X BMC Oral Health. 2024; 24(1):552.

PMID: 38735923 PMC: 11089774. DOI: 10.1186/s12903-024-04338-y.


References
1.
Li C, Song Y, Higuera E, Luo Z . Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci. 2004; 24(39):8494-9. PMC: 1635787. DOI: 10.1523/JNEUROSCI.2982-04.2004. View

2.
Werner M, Perkins F, Holte K, Pedersen J, Kehlet H . Effects of gabapentin in acute inflammatory pain in humans. Reg Anesth Pain Med. 2001; 26(4):322-8. DOI: 10.1053/rapm.2001.25070. View

3.
Hunter J, Gogas K, Hedley L, JACOBSON L, Kassotakis L, Thompson J . The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol. 1997; 324(2-3):153-60. DOI: 10.1016/s0014-2999(97)00070-8. View

4.
Field M, Oles R, Lewis A, McCleary S, Hughes J, Singh L . Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol. 1997; 121(8):1513-22. PMC: 1564875. DOI: 10.1038/sj.bjp.0701320. View

5.
Levendoglu F, Ogun C, Ozerbil O, Ogun T, Ugurlu H . Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine (Phila Pa 1976). 2004; 29(7):743-51. DOI: 10.1097/01.brs.0000112068.16108.3a. View